Trial Profile
A Multi-centre, Retrospective study to evaluate the safety and efficacy of Sunitinib in patients with Advanced Radioiodine Refractory Thyroid Carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Feb 2018
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 19 Feb 2018 New trial record